NattoPharma Awarded Grant from Norwegian Research Council
New grant will fund substantiating MenaQ7 Vitamin K2 effect on calcium metabolism
OSLO, NORWAY and METUCHEN, NJ (April 18, 2017) – The Norwegian Research Council has awarded a grant to NattoPharma to fund a 4-year project to document the effects of calcium metabolism in the body based on the presence or absence of Vitamin K2, MK7. The project will utilize NattoPharma’s MenaQ7 ® Vitamin K2 as MK-7 and the research part will be conducted at the Maastricht University in the Netherlands in the Department of Biochemistry under the guidance of Dr. Leon Schurgers, Senior Scientist and Associate Professor of Biochemistry at Maastricht and CARIM, the Cardiovascular Research Institute of Maastricht.
In this research, Nattopharma together with the Maastricht University will study the utilisation of calcium in preclinical models for postmenopausal bone loss and chronic kidney failure to determine how supplemental calcium is metabolized in the presence or absence of supplemental vitamin K2, MK7.
“This study will help to provide further evidence that calcium without adequate Vitamin K2 consumption might end up in the soft tissues where it is not wanted, rather than in the bone matrix, where it is needed,” says Dr. Schurgers. In a recent study by “Bolland et al. it was shown that calcium supplementation of postmenopausal women was associated a beneficial effect on bone, but also with increased myocardial infarction, suggesting detrimental effects on the vascular system possibly by increased vascular calcification. As calcium supplementation is needed for bone, the precipitation in the vessel wall needs to be inhibited.”
NattoPharma is rightfully excited about this new study, which should add to the evidence confirming Vitamin K2’s role as a cardiovascular supporter, including the ground-breaking three-year interventional study1 the company sponsored that confirmed adding 180mcg of MenaQ7 ® Vitamin K2 as MK-7 to one’s daily intake improves arterial health and flexibility.
“This will be the first study that demonstrates K2’s impact on calcium metabolism in vivo ; however, we have shown in human studies with healthy participants that the progression of hardening of the arteries can be halted and even regressed,” adds Dr. Hogne Vik, NattoPharma Chief Medical Officer. “Calcium supplement manufacturers must recognize the importance of pairing calcium with Vitamin K2. They cannot ignore the growing body of evidence that K2 is required for the body to properly metabolize and utilize calcium.”
1 Knapen MH et al, Braam LAJL, Drummen NE, Bekers O, Hoeks APG, Vermeer C. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women: double-blind randomised clinical trial. Thrombosis and Haemostasis. 2015 113 5: 1135-1144. doi: 10.1160/TH14-08-0675.
# # #
About NattoPharma and MenaQ7®
NattoPharma ASA, based in Norway, is the world’s leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK-7) with guaranteed actives and stability, clinical substantiation, and international patents granted and pending. The company has a multi-year research and development program to substantiate and discover the health benefits of vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPahrma USA, Inc., in Metuchen, NJ. For more information, visit nattopharma.com or menaq7.com.
For more information, please contact:
Kate Quackenbush, NattoPharma Director of Communications